242 related articles for article (PubMed ID: 30380837)
1. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.
Corpas-Lopez V; Moniz S; Thomas M; Wall RJ; Torrie LS; Zander-Dinse D; Tinti M; Brand S; Stojanovski L; Manthri S; Hallyburton I; Zuccotto F; Wyatt PG; De Rycker M; Horn D; Ferguson MAJ; Clos J; Read KD; Fairlamb AH; Gilbert IH; Wyllie S
ACS Infect Dis; 2019 Jan; 5(1):111-122. PubMed ID: 30380837
[TBL] [Abstract][Full Text] [Related]
2. Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes.
Paape D; Bell AS; Heal WP; Hutton JA; Leatherbarrow RJ; Tate EW; Smith DF
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3363. PubMed ID: 25522361
[TBL] [Abstract][Full Text] [Related]
3. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
4. Novel Thienopyrimidine Inhibitors of
Bell AS; Yu Z; Hutton JA; Wright MH; Brannigan JA; Paape D; Roberts SM; Sutherell CL; Ritzefeld M; Wilkinson AJ; Smith DF; Leatherbarrow RJ; Tate EW
J Med Chem; 2020 Jul; 63(14):7740-7765. PubMed ID: 32575985
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Zahid MSH; Johnson MM; Tokarski RJ; Satoskar AR; Fuchs JR; Bachelder EM; Ainslie KM
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():125-132. PubMed ID: 31493763
[TBL] [Abstract][Full Text] [Related]
6. N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis.
Brannigan JA; Smith BA; Yu Z; Brzozowski AM; Hodgkinson MR; Maroof A; Price HP; Meier F; Leatherbarrow RJ; Tate EW; Smith DF; Wilkinson AJ
J Mol Biol; 2010 Mar; 396(4):985-99. PubMed ID: 20036251
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.
Nühs A; De Rycker M; Manthri S; Comer E; Scherer CA; Schreiber SL; Ioset JR; Gray DW
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004094. PubMed ID: 26407168
[TBL] [Abstract][Full Text] [Related]
8. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
De Rycker M; Hallyburton I; Thomas J; Campbell L; Wyllie S; Joshi D; Cameron S; Gilbert IH; Wyatt PG; Frearson JA; Fairlamb AH; Gray DW
Antimicrob Agents Chemother; 2013 Jul; 57(7):2913-22. PubMed ID: 23571538
[TBL] [Abstract][Full Text] [Related]
10. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.
Bell AS; Mills JE; Williams GP; Brannigan JA; Wilkinson AJ; Parkinson T; Leatherbarrow RJ; Tate EW; Holder AA; Smith DF
PLoS Negl Trop Dis; 2012; 6(4):e1625. PubMed ID: 22545171
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Pharmacological Studies of 4-Hydroxyphenyl-Derived Phosphonium Salts Active in a Mouse Model of Visceral Leishmaniasis.
Manzano JI; Cueto-Díaz EJ; Olías-Molero AI; Perea A; Herraiz T; Torrado JJ; Alunda JM; Gamarro F; Dardonville C
J Med Chem; 2019 Dec; 62(23):10664-10675. PubMed ID: 31702921
[TBL] [Abstract][Full Text] [Related]
13. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis.
Kashif M; Manna PP; Akhter Y; Alaidarous M; Rub A
Infect Disord Drug Targets; 2017; 17(2):120-129. PubMed ID: 28034363
[TBL] [Abstract][Full Text] [Related]
14. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis.
Chakrabarti G; Basu A; Manna PP; Mahato SB; Mandal NB; Bandyopadhyay S
J Antimicrob Chemother; 1999 Mar; 43(3):359-66. PubMed ID: 10223591
[TBL] [Abstract][Full Text] [Related]
15. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
17. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
[TBL] [Abstract][Full Text] [Related]
18. Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa.
Das A; Jawed JJ; Das MC; Sandhu P; De UC; Dinda B; Akhter Y; Bhattacharjee S
Int J Antimicrob Agents; 2017 Oct; 50(4):512-522. PubMed ID: 28669838
[TBL] [Abstract][Full Text] [Related]
19. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Wyllie S; Brand S; Thomas M; De Rycker M; Chung CW; Pena I; Bingham RP; Bueren-Calabuig JA; Cantizani J; Cebrian D; Craggs PD; Ferguson L; Goswami P; Hobrath J; Howe J; Jeacock L; Ko EJ; Korczynska J; MacLean L; Manthri S; Martinez MS; Mata-Cantero L; Moniz S; Nühs A; Osuna-Cabello M; Pinto E; Riley J; Robinson S; Rowland P; Simeons FRC; Shishikura Y; Spinks D; Stojanovski L; Thomas J; Thompson S; Viayna Gaza E; Wall RJ; Zuccotto F; Horn D; Ferguson MAJ; Fairlamb AH; Fiandor JM; Martin J; Gray DW; Miles TJ; Gilbert IH; Read KD; Marco M; Wyatt PG
Proc Natl Acad Sci U S A; 2019 May; 116(19):9318-9323. PubMed ID: 30962368
[TBL] [Abstract][Full Text] [Related]
20. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Tegazzini D; Díaz R; Aguilar F; Peña I; Presa JL; Yardley V; Martin JJ; Coteron JM; Croft SL; Cantizani J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3524-32. PubMed ID: 27021313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
